NeuroOne Set to Join Russell Microcap Index, Boosting Investor Visibility

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, announced it is expected to join the Russell Microcap Index as part of the first semi-annual 2026 Russell indexes reconstitution. The preliminary inclusion lists were published by FTSE Russell on May 22, May 29, and June 5, 2026, and the new indexes will take effect after the US market close on June 26, 2026.

CEO Dave Rosa expressed optimism about the inclusion, stating, "We believe our inclusion reflects the commercial momentum we have built across our portfolio of FDA-cleared electrode and ablation technologies, and the increasing recognition of NeuroOne within the investment community. We expect membership in the index to expand our visibility among institutional investors and broaden our shareholder base."

NeuroOne markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These products aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes. The company is also researching drug delivery, basivertebral nerve ablation, and spinal cord stimulation.

The inclusion in the Russell Microcap Index is significant for NeuroOne as it typically leads to increased visibility among institutional investors and potential index fund buying. The move from annual to semi-annual reconstitution by FTSE Russell, starting in 2026, could also affect the timing of such inclusions. For more information about NeuroOne and its technologies, visit their website at nmtc1.com.

Forward-looking statements in the press release highlight risks and uncertainties that could affect actual results. These include partnership outcomes, supply chain disruptions, technology performance, capital requirements, reimbursement issues, and regulatory changes. NeuroOne undertakes no obligation to update these statements.